PHXM Key Statistics, Chart & Performance
The current stock price of PHXM is 3.1 USD. In the past month the price decreased by -29.55%.
PHXM Latest News, Press Relases and Analysis
PHXM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.1 | 402.43B | ||
| AMGN | AMGEN INC | 15.8 | 186.02B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 156.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.98 | 110.02B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.33 | 82.00B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 884.76 | 59.61B | ||
| INSM | INSMED INC | N/A | 44.31B | ||
| NTRA | NATERA INC | N/A | 32.96B | ||
| BIIB | BIOGEN INC | 10.88 | 26.71B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.42 | 20.93B | ||
| INCY | INCYTE CORP | 16.27 | 20.51B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.22B |
Related stock screener links
About PHXM
Company Profile
Phaxiam Therapeutics SA is a FR-based company operating in Biotechnology industry. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The firm relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.
Company Info
PHAXIAM Therapeutics SA
60 avenue Rockefeller
Lyon AUVERGNE-RHONE-ALPES FR
Employees: 49
Phone: 33478744438
PHAXIAM Therapeutics SA / PHXM FAQ
What does PHXM do?
Phaxiam Therapeutics SA is a FR-based company operating in Biotechnology industry. The company is headquartered in Lyon, Auvergne-Rhone-Alpes and currently employs 49 full-time employees. The company went IPO on 2013-05-07. PHAXIAM Therapeutics SA, formerly known as ERYTECH PHARMA SA, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The firm relies on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics SA is developing a portfolio of phages targeting three of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. The company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer.
What is the current price of PHXM stock?
The current stock price of PHXM is 3.1 USD. The price decreased by -0.64% in the last trading session.
Does PHXM stock pay dividends?
PHXM does not pay a dividend.
What is the ChartMill technical and fundamental rating of PHXM stock?
PHXM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is PHAXIAM Therapeutics SA (PHXM) stock traded?
PHXM stock is listed on the Nasdaq exchange.
What is the analyst forecast for PHXM stock?
8 analysts have analysed PHXM and the average price target is 10.17 USD. This implies a price increase of 228.04% is expected in the next year compared to the current price of 3.1.
What is the market capitalization of PHXM stock?
PHAXIAM Therapeutics SA (PHXM) has a market capitalization of 18.83M USD. This makes PHXM a Nano Cap stock.
PHXM Technical Analysis
PHXM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHXM. PHXM has a bad profitability rating. Also its financial health evaluation is rather negative.
PHXM Financial Highlights
Over the last trailing twelve months PHXM reported a non-GAAP Earnings per Share(EPS) of -0.04. The EPS increased by 99.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.35% | ||
| ROE | -0.62% | ||
| Debt/Equity | 0.3 |
PHXM Forecast & Estimates
8 analysts have analysed PHXM and the average price target is 10.17 USD. This implies a price increase of 228.04% is expected in the next year compared to the current price of 3.1.
For the next year, analysts expect an EPS growth of 77.73% and a revenue growth -100% for PHXM